skip to Main Content

A MOLECULE THAT SAVES LIVES

Heparin is the anticoagulant most frequently used in the prevention and treatment of thrombosis. One in four people worldwide die from causes related to this disease.

It has a solid scientific basis and its efficacy and safety have been amply demonstrated.

It is on the World Health Organization’s list of essential medicines and saves more than 100 million lives each year.

Although it’s a hundred-year-old molecule, new applications related to anti-tumor, anti-inflammatory and anti-viral activity are being studied.

Heparin is the anticoagulant most frequently used in the prevention and treatment of thrombosis. One in four people worldwide die from causes related to this disease.

It is on the World Health Organization’s list of essential medicines and saves more than 100 million lives each year.

It has a solid scientific basis and its efficacy and safety have been amply demonstrated.

Although it’s a hundred-year-old molecule, new applications related to anti-tumor, anti-inflammatory and anti-viral activity are being studied.

Heparin is a highly-sulfated glycosaminoglycan, a natural substance composed of several molecules with properties that inhibit blood clotting. As a result of these characteristics, heparin is the most used anticoagulant and anti-thrombotic drug worldwide.

Heparin is a natural polysaccharide that contains a large number of linear and polydisperse chains. The molecular weight of natural heparin can vary from 3,000 to 30,000 Daltons (Da), whilst the average molecular weight of pharmaceutical-grade heparin is from 15 to 19,000 Da. Heparin chains are composed of long, fully-sulfated segments with interspersed low sulfated domains.

It is the medicine
anticoagulant and antithrombotic
most used in the world

UNFRACTIONED HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN

There are two types of heparin as anticoagulants: heparin sodium or unfractioned heparin (UFH) and fractioned heparin, also called low-molecular-weight heparin (LMWH)

UFH is for hospital use and is mainly used intravenously.

LMWH, thanks to their lower non-hemorrhagic side effects, can be used for both hospital use as well as for intramuscular self-administration. These heparins have been replacing unfractioned heparins and have become the first choice anticoagulants for the prevention and treatment of venous thrombosis.

LMWHs are obtained through various methods of chemical and enzymatic depolymerization from pharmaceutical-grade UFH.

Each depolymerization method results in different LMWHs. Each one has a distinct and specific fingerprint due to their differences in chemical structure and molecular weight profile.

Typically, LMWHs have an average molecular weight between 3,000 and 7,000 Da. Unlike unfractioned heparin, LMWH chains are too small to form a ternary complex with thrombin and antithrombin. Consequently, they exert their anticoagulant activity through the inhibition of factor Xa.

The advantages of LMWH over unfractioned heparin are:

• Better bioavailability: this type of heparin doesn’t bind to proteins or endothelial cells, nor is it neutralized by plasma proteins. Therefore, the complete dosage performs the anticoagulant function.

• A more predictable dose-response. There is no need to monitor or adjust the dose during its administration.

• Its plasma half-life is longer than that of unfractioned heparin, meaning it can be administered subcutaneously once or twice a day.

MECHANISM OF ACTION

Heparin is a natural substance that acts by interacting with the blood’s coagulation cascade and helps the blood anticoagulation process. It mainly acts on thrombin which plays an important role in blood clot formation. Classic heparin exerts its anticoagulant effect by accelerating the formation of molecular complexes between antithrombin III and factors II (prothrombin), IX, X, XI and XII which are inactivated.

Author: Martin Wardle

AN ESSENTIAL MEDICINE

Heparin can interact and regulate the activities of a wide range of proteins that are essential for important biological processes such as:

  • Blood clotting
  • Infection of pathogens
  • Cell differentiation
  • Cell growth and migration
  • Inflammation

Heparin can interact
and regulate the activities of
a wide range of proteins

The general medical uses of heparin are the following:

  • Acute myocardial infarction
  • Curative and prophylactic treatment of arterial and venous thromboembolism
  • Pulmonary thromboembolism
  • Peripheral arterial diseases
  • Arteriosclerosis
  • Extracorporeal circulation
  • Anticoagulant coating for medical devices
  • Hemodialysis
  • Prevention of deep venous and pulmonary thromboembolism
    during pregnancy
  • Extracorporeal therapies such as oxygenation of the heart and lungs and hepatic dialysis
  • Open heart surgery
  • Deep venous thrombosis
  • Vitreoretinal surgery
  • External use for the treatment of ulcers
  • External use for the treatment of varicose veins

However, the potential of the heparin molecule and its derivatives for the development of new drugs is huge. Heparin activity is being studied in the treatment of cancer, malaria, chronic obstructive pulmonary disease (COPD), organ transplantation, arthritis, cystic fibrosis, asthma or pulmonary emphysema, amongst others.

DID YOU KNOW THAT HEPARIN…

MANUFACTURING SITE

C/ Antic Camí de la Tordera, 109-119
08389 Palafolls (Barcelona)
Tel: +34 93 765 03 90

CORPORATE OFFICES

Av. Països Catalans 34, planta 2ª
08950 Esplugues de Llobregat
(Barcelona- Spain)
Tel: +34 93 490 49 08

CONTACT WITH US

CONTACT US

Name and Surname:
Email:
Company:
Country:
Message:
BIOIBERICA S.A.U. as the data controller will process your data for the purpose of replying to your query or request. You may access, rectify and erase your data, and also exercise other rights by consulting the additional detailed information on data protection in our Privacy Policy

I have read and accept the conditions contained in the privacy policy on processing of my data to manage my query or request.

We would like you to give us your consent to:

Send you commercial information about BIOIBERICA S.A.U.’s products, services and new features

© 2019. Bioiberica S.A.U. All rights reserved

MANUFACTURING SITE

C/ Antic Camí de la Tordera, 109-119
08389 Palafolls (Barcelona)
Tel: +34 93 765 03 90

CORPORATE OFFICES

Av. Països Catalans 34, planta 2ª
08950 Esplugues de Llobregat
(Barcelona- Spain)
Tel: +34 93 490 49 08

CONTACT WITH US

CONTACT US

Name and Surname:
Email:
Company:
Country:
Message:
BIOIBERICA S.A.U. as the data controller will process your data for the purpose of replying to your query or request. You may access, rectify and erase your data, and also exercise other rights by consulting the additional detailed information on data protection in our Privacy Policy

I have read and accept the conditions contained in the privacy policy on processing of my data to manage my query or request.

We would like you to give us your consent to:

Send you commercial information about BIOIBERICA S.A.U.’s products, services and new features

© 2019. Bioiberica S.A.U. All rights reserved

You are about to access information on our medicines and medical devices aimed exclusively at healthcare professionals.

By virtue of Spanish Royal Decree 1416/1994 of 25 June regulating the advertising of medicinal products for human use, Spanish Royal Decree 1591/2009 of 16 October regulating medical devices and Law 29/2006 of 26 July on the guarantees and rational use of medicines and health products, in this section Bioibérica can only offer advertising content of prescription medicines to health personnel authorised to prescribe or dispense them.

I am a health professional authorised to prescribe or dispense, or a pharma company professional.

You must be a health professional
authorised to acces this page.
Back To Top